CGEM · Cullinan Therapeutics

The thesis

Cullinan Therapeutics is more likely to lag the S&P 500 over the next three months. The shares closed at $10.19 on 12 November 2026, the session in which partner Taiho Oncology announced it had completed the first-line zipalertinib new drug application (NDA). The December CLN-978 multi-dose autoimmune data decide whether the pipeline is being re-priced or simply sold.

The completed filing removes one of the open milestones. The shares fell anyway: from $11.35 on 11 November 2026 to $10.19 on 12 November 2026, and from $20.34 on 14 August 2026 to the latest close, a three-month change of −49.9%. The last close is below the 50-day average of $16.11 and the 200-day average of $15.83, and 56.1% below the 52-week intraday high of $23.19 set on 26 August 2026.

Wedbush maintained its Outperform rating and raised its price target to $44 on 11 November 2026, per company news. The gap between that target and the share price shows that analysts have not changed their view of the programs while the shares kept falling. No company filing explains the decline on its own.

Bullish and bearish views on Cullinan Therapeutics, Inc.

The bull case on Cullinan Therapeutics, Inc. (CGEM), in brief: first-line filing is complete and early. The bear case: the selling has continued through good news.

Bull case

• First-line filing is complete and early. Taiho Oncology announced on 12 November 2026 that it completed the NDA for zipalertinib plus platinum chemotherapy in previously untreated EGFR exon 20 insertion lung cancer, under the FDA's Real-Time Oncology Review program. Cullinan's 1 October 2026 8-K had targeted completion by year-end 2026. No FDA acceptance or action date has been announced.
• Phase 3 efficacy was clear. The 13 September 2026 REZILIENT3 release reported median progression-free survival of 14.5 months with zipalertinib plus chemotherapy versus 8.5 months with chemotherapy alone, a hazard ratio of 0.50 (95% confidence interval 0.34–0.73).
• Lupus data were clean at small scale. On 9 November 2026 Cullinan reported that 8 of 9 evaluable patients treated with velinotamig had a drop of at least four points in the SLEDAI-2K lupus disease activity score. Four patients with elevated proteinuria reached complete renal response, with no dose-limiting toxicities, immune effector cell–associated neurotoxicity syndrome (ICANS) or grade 3 or higher cytokine release syndrome.
• Approval payments are defined. Cullinan is eligible for $30 million on US second-line approval, with an FDA action date of 27 February 2027, and $100 million on first-line approval, plus a 50/50 US profit share (third-quarter 2026 report, 10 November 2026).
• Runway extends into 2029. Cash, investments and interest receivable were $313.8 million at 30 September 2026, and the company reiterated its runway guidance into 2029.
• Analysts keep raising targets. Wedbush raised its target to $44 on 11 November 2026, the day after the third-quarter report.

Bear case

• The selling has continued through good news. The shares closed at $10.19 on 12 November 2026, down from $11.73 on 9 November 2026, and a day after the filing news they sit under both the 50-day and 200-day averages.
• Cash is falling. Cash and investments were $313.8 million at 30 September 2026 versus $439.0 million at 31 December 2025. The nine-month net loss was $152.8 million and the third-quarter net loss was $49.4 million (10 November 2026 report). A pre-revenue company with a lower share price is more exposed to an equity raise around the December data.
• Milestones have slipped before. On 24 September 2026 Cullinan moved CLN-978 rheumatoid arthritis data from the third quarter to December. The shares fell 8.54% that day, per StockTitan.
• Side effects and survival are unresolved. REZILIENT3 reported grade 3 or higher adverse events in 87.1% of combination patients versus 54.4% on chemotherapy. The overall-survival hazard ratio was 0.72 (95% confidence interval 0.42–1.23) at 30% maturity (13 September 2026 release).
• The lupus sample is small. The velinotamig dataset covers 12 treated patients at a 8 September 2026 data cutoff, too few to support a conclusion on response rates.
• An insider sold into the decline. Chief Scientific Officer Jennifer Michaelson sold 4,000 shares at $12.36 on 5 November 2026 after exercising 3,805 options at $4.30, under a Rule 10b5-1 plan (SEC Form 4, filed 6 November 2026). The same plan covered a sale of 8,000 shares at $21.57 on 8 September 2026.

Price setup

The shares closed at $10.19 on 12 November 2026, the lowest close among the sessions since 5 November 2026 ($10.80 on 5 November 2026, $11.31 on 6 November 2026, $11.23 on 10 November 2026, $11.35 on 11 November 2026). The 50-day average is $16.11 and the 200-day average is $15.83, so the shares trade well under both. The 52-week closing low is $8.27, set on 13 November 2025.

The 52-week intraday high is $23.19 on 26 August 2026. The $12.49 close of 4 November 2026 and the $13.51 level in the kill line are the nearest prices above the recent range.

Third-quarter results and the first-line filing are now out. The next dated events are the UBS healthcare conference chat on 17 November 2026, the ASH poster on 13 December 2026 and the company-guided December CLN-978 webcast. No SEC filings for an equity offering are listed in the latest filings, which show the 10-Q on 10 November 2026 and the two Form 4 filings.

Catalysts ahead

• 17 November 2026: Management fireside chat at the UBS healthcare conference. Management commentary on the December readouts and the completed first-line filing; new data is not expected, per Biotech Distilled.
• 13 December 2026: CLN-049 updated Phase 1 data at the ASH poster session. Shows whether the FLT3 engager's leukemia response rates hold as the potentially registrational Phase 2 study enrolls.
• ~15 December 2026 (est.): CLN-978 multi-dose webcast in lupus, rheumatoid arthritis and Sjögren's disease. Settles whether repeat dosing extends single-dose remissions without added cytokine release or neurotoxicity; the exact date is unannounced.
• 27 February 2027: FDA action date for second-line zipalertinib. First approval clock; US approval triggers a $30 million payment to Cullinan.

What would change the view

A daily close above $13.51, over the $12.49 close of 4 November 2026, which would show the shares leading again. A December CLN-978 multi-dose readout with durable remissions and no grade 2 or higher cytokine release syndrome or neurotoxicity would also show the shares leading.

What it trades with

Cullinan trades with small and mid-cap clinical-stage biotech, and single-headline sessions have moved it by double digits. Its lung-cancer value depends on Taiho Oncology's co-development, and its autoimmune value depends on T cell engager safety and durability data from peers and from its own CLN-978 and velinotamig programs. Moves in the XBI biotech index and in competing exon 20 lung-cancer drugs, such as amivantamab, carry through to the shares.